Convalescent plasma therapy and long-term SARS-COV-2 antiviral immune response in a prospective cohort of patients with COVID-19.

ABSTRACT: During the SARS-CoV-2 pandemic, the use of convalescent plasma (CP) in high-risk patients was proposed and widely implemented in several countries as a potential COVID-19 therapy. Nonetheless, CP therapy's impact on immune response is nowadays poorly understood, including the correlation between IgG levels, neutralization capacity, and cellular immune response against SARS-CoV-2. Here we evaluated, in a cohort of patients with COVID-19 requiring hospitalization and having received or not CP, as well as in CP donors (recovered from mild disease), the humoral and cellular immune response assessed by titers of SARS-CoV-2 IgG, neutralizing antibodies, and IFN-γ⁺/IL-2⁺ ELISpot during the first month (early) and up to nine months (long-term) after symptom onset. Results sho

SUBMITTER: Barrera A 

PROVIDER: S-EPMC12307662 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature